Annals of Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 101903 - 101903
Published: March 1, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes chronic globally. Based on 2023 definition, MASLD characterized by presence metabolic dysfunction and limited alcohol consumption (<140 grams/week for women, <210 men). Given significant burden in Latin America, this guidance was developed American Association Study Liver (ALEH) Working Group to address key aspects its clinical assessment therapeutic strategies. In ultrasonography recommended as initial screening tool hepatic steatosis due accessibility, while Fibrosis-4 (FIB-4) preferred fibrosis risk stratification, with further evaluation using more specific techniques (i.e., vibration-controlled transient elastography or Enhanced Fibrosis [ELF] test). A Mediterranean diet advised all patients, a target 7-10% weight loss those excess weight. Complete abstinence patients fibrosis, smoking cessation encouraged regardless stage. Pharmacological options should be tailored based steatohepatitis, weight, diabetes, including resmetirom, incretin-based therapies, pioglitazone, sodium-glucose cotransporter-2 inhibitors. Bariatric surgery may considered obesity unresponsive lifestyle medical interventions. Hepatocellular carcinoma cirrhotic consideration given advanced individual risk. Finally, routine cardiovascular proper diabetes prevention management remain crucial MASLD.
Language: Английский
Citations
0Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy
Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2024, Volume and Issue: 20(9), P. 893 - 905
Published: Aug. 30, 2024
The course of HIV infection has changed radically with the introduction antiretroviral therapy (ART), which significantly reduced mortality and improved quality life. However, drugs can cause adverse effects, including cardiometabolic complications diseases, are among most common. Compared to adult population, there fewer studies in pediatric population on treatment-related complications. purpose this review is provide an update literature regarding diseases children adolescents HIV.
Language: Английский
Citations
1Unraveling the safety and efficacy of semaglutide for people living with HIV and metabolic co-morbidities
Expert Opinion on Drug Safety, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 4
Published: Nov. 28, 2024
Language: Английский
Citations
0Optimizing Cardiometabolic Risk in People Living with Human Immunodeficiency Virus: A Deep Dive into an Important Risk Enhancer
American Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: 20, P. 100888 - 100888
Published: Oct. 30, 2024
Effective antiretroviral therapy (ART) is now nearly ubiquitous. However, the survival benefits conferred with ART contribute to an aging human immunodeficiency virus (HIV) population and increased risk of chronic diseases, like atherosclerotic cardiovascular disease (ASCVD). Furthermore, HIV a known enhancer ASCVD acknowledged as such in current 2018 AHA/ACC Blood Cholesterol guidelines [1]. This makes factor identification modification among people living (PLWH) increasing importance prevent events. In this review, we aim summarize epidemiology pathogenesis how linked atherogenesis discuss cardiometabolic specific PLWH, covering obesity, hypertension, insulin resistance, metabolic dysfunction-associated steatotic liver disease, dyslipidemia.
Language: Английский
Citations
0MASLD in Special Populations
Published: Jan. 1, 2024
Language: Английский
Citations
0